The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial

Several large phase iii trials have demonstrated that tamoxifen—and more recently, raloxifene—can effectively reduce the incidence of invasive breast cancer by 50%. However, these selective estrogen receptor modulators can also be associated with several rare, but serious, adverse events. Recently,...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, H., Johnston, D., Pater, J., Goss, P.
Formato: Texto
Lenguaje:English
Publicado: Multimed Inc. 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1899358/
https://www.ncbi.nlm.nih.gov/pubmed/17593981
_version_ 1782133939612155904
author Richardson, H.
Johnston, D.
Pater, J.
Goss, P.
author_facet Richardson, H.
Johnston, D.
Pater, J.
Goss, P.
author_sort Richardson, H.
collection PubMed
description Several large phase iii trials have demonstrated that tamoxifen—and more recently, raloxifene—can effectively reduce the incidence of invasive breast cancer by 50%. However, these selective estrogen receptor modulators can also be associated with several rare, but serious, adverse events. Recently, the third-generation aromatase inhibitors (ais) have demonstrated excellent efficacy in adjuvant breast cancer trials, and they show particular promise in the breast cancer prevention setting. The National Cancer Institute of Canada Clinical Trials Group (ncic ctg) has developed a randomized phase iii study to determine the efficacy of an ai (exemestane) to reduce the incidence of invasive breast cancer in postmenopausal women at an increased risk for developing breast cancer. The ncic ctg map.3 (ExCel) trial is a double-blind placebo-controlled multicentre, multinational trial. Based on the known preclinical and clinical profile of the ais, a greater reduction in breast cancer incidence with fewer side effects is hypothesized with this class of agents than with tamoxifen or raloxifene.
format Text
id pubmed-1899358
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Multimed Inc.
record_format MEDLINE/PubMed
spelling pubmed-18993582007-06-26 The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial Richardson, H. Johnston, D. Pater, J. Goss, P. Curr Oncol Canadian Centre Activities Several large phase iii trials have demonstrated that tamoxifen—and more recently, raloxifene—can effectively reduce the incidence of invasive breast cancer by 50%. However, these selective estrogen receptor modulators can also be associated with several rare, but serious, adverse events. Recently, the third-generation aromatase inhibitors (ais) have demonstrated excellent efficacy in adjuvant breast cancer trials, and they show particular promise in the breast cancer prevention setting. The National Cancer Institute of Canada Clinical Trials Group (ncic ctg) has developed a randomized phase iii study to determine the efficacy of an ai (exemestane) to reduce the incidence of invasive breast cancer in postmenopausal women at an increased risk for developing breast cancer. The ncic ctg map.3 (ExCel) trial is a double-blind placebo-controlled multicentre, multinational trial. Based on the known preclinical and clinical profile of the ais, a greater reduction in breast cancer incidence with fewer side effects is hypothesized with this class of agents than with tamoxifen or raloxifene. Multimed Inc. 2007-06 /pmc/articles/PMC1899358/ /pubmed/17593981 Text en 2007 Multimed Inc.
spellingShingle Canadian Centre Activities
Richardson, H.
Johnston, D.
Pater, J.
Goss, P.
The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial
title The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial
title_full The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial
title_fullStr The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial
title_full_unstemmed The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial
title_short The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial
title_sort national cancer institute of canada clinical trials group map.3 trial: an international breast cancer prevention trial
topic Canadian Centre Activities
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1899358/
https://www.ncbi.nlm.nih.gov/pubmed/17593981
work_keys_str_mv AT richardsonh thenationalcancerinstituteofcanadaclinicaltrialsgroupmap3trialaninternationalbreastcancerpreventiontrial
AT johnstond thenationalcancerinstituteofcanadaclinicaltrialsgroupmap3trialaninternationalbreastcancerpreventiontrial
AT paterj thenationalcancerinstituteofcanadaclinicaltrialsgroupmap3trialaninternationalbreastcancerpreventiontrial
AT gossp thenationalcancerinstituteofcanadaclinicaltrialsgroupmap3trialaninternationalbreastcancerpreventiontrial
AT richardsonh nationalcancerinstituteofcanadaclinicaltrialsgroupmap3trialaninternationalbreastcancerpreventiontrial
AT johnstond nationalcancerinstituteofcanadaclinicaltrialsgroupmap3trialaninternationalbreastcancerpreventiontrial
AT paterj nationalcancerinstituteofcanadaclinicaltrialsgroupmap3trialaninternationalbreastcancerpreventiontrial
AT gossp nationalcancerinstituteofcanadaclinicaltrialsgroupmap3trialaninternationalbreastcancerpreventiontrial